A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. The starting dose ...

Novo Nordisk’s NOVO.B1.17%increase; green up pointing triangle Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish ...

Shortly after scoring a historic FDA nod for its Wegovy pill, Novo Nordisk is off to the races with the oral obesity med’s launch. The once-daily pill officially debuted in the U.S. Monday, with the ...

American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S. The cash prices for the drug, called the Wegovy ...

Novo launches Wegovy pill in competitive obesity drug market Eli Lilly expects weight-loss pill decision later this year Novo targets self-pay market with oral option over injectable Starter dose of ...

Jan. 5 (UPI) --Pharmaceutical company Novo Nordisk announced Monday that a new pill-version of its GLP-1 weight-loss drug is now "broadly available" at U.S. pharmacies. The Wegovy pill, available in ...

Novo Nordisk A/S is rated a buy, driven by FDA approval of its oral Wegovy, strong fundamentals, and attractive valuation versus Eli Lilly. Recent clinical data and first-mover advantage position ...

Novo Nordisk launched the first GLP-1 weight-loss pill Monday with a pledge that manufacturing investments will enable the drugmaker to avoid the type of shortages that plagued the rollout of its ...

Novo Nordisk has launched its first oral GLP-1 weight-loss pill in the United States, expanding beyond injectable treatments that have reshaped the obesity market. GoodRx is offering a major discount.

Americans can now purchase a starter dose of Novo Nordisk’s weight loss drug Wegovy in pill form, the company announced Monday, pledging widespread availability. The 1.5 milligram starter dose of a ...

Ozempic has become a phenomenon, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. With ...

COPENHAGEN, Jan 5 (Reuters) - Denmark's Novo Nordisk will offer its 1.5 and 4 milligram Wegovy weightloss pills at $149 per month to self-paying patients in the United States from January 5, it said ...